Product / Company Performance | BARE BONES

Strategic Initiatives Product / Company Performance Reimbursement / Regulatory Research / Technology Financials 510(k)s
Take me to ORTHOKNOW! BARE BONES content is posted to these pages in real time. Monthly compilations are available in PDF form. Dec 2019 Issue Nov 2019 Issue Oct 2019 Issue Product / Company Performance Orthofix will restate financial statements for FY11, '12 and 13 and 1Q14 by end of 3Q14. The company determined that certain entries in these statements were not properly accounted for under U.S. GAAP. OFIX expects to reduce net sales by US $6MM, $9MM, $2MM and $3MM for the periods, respectively. (Orthofix International N.V., 8/19/14)